8-K: Phio Pharma's PH-762 Advances to Key FDA Toxicology Study

Phio Pharmaceuticals announced FDA acceptance of its PH-762 nonclinical study design, paving the way for a toxicology study in Q1 2026 and further drug development.

Summary

• The FDA has accepted Phio Pharmaceuticals' nonclinical protocol study design for PH-762, a significant step in its drug development program.
• A toxicology study, required by the FDA prior to commencing a human pivotal trial, is scheduled to begin in the First Quarter 2026.
• Initiatives are continuing to advance the delivery of commercially viable drug product in 2026 that meets FDA's current Good Manufacturing Practices (cGMP).
• A portion of the company's recent financing is being directed to these two major initiatives: the toxicology study and manufacturing advancements.
• Positive interim safety and efficacy results were reported from the ongoing Phase 1b dose escalation clinical trial with PH-762 for the treatment of skin cancer.
• A total of 18 patients with cutaneous carcinomas have completed treatment across five dose escalating cohorts in the Phase 1b trial.
• Among 16 patients with cutaneous squamous cell carcinoma (cSCC), there were 6 complete responses (100% clearance), 2 near complete responses (>90% clearance), and 2 partial responses (>50% clearance).
• One patient with metastatic Merkel cell carcinoma had a partial response (>50% clearance).
• No patients in the study exhibited clinical progression of disease, and PH-762 has been well tolerated with no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects.

Sentiment

Score: 7

Explanation: The filing indicates significant positive progress in the drug development pathway for PH-762, with FDA acceptance of study design and encouraging interim clinical trial results. While some patients showed non-response, the overall safety profile and complete responses are strong positives. The timeline for the toxicology study in Q1 2026 and manufacturing in 2026 provides clear next steps, but also indicates that pivotal trials are still some time away.

Positives

• FDA acceptance of the nonclinical protocol study design for PH-762 marks a significant regulatory milestone, progressing the drug toward NDA approval.
• Positive interim safety and efficacy results from the Phase 1b trial, including complete and near-complete responses in cSCC patients, are encouraging.
• PH-762 has been well tolerated in all enrolled patients, with no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects observed.
• No patients in the Phase 1b study exhibited clinical progression of disease.
• Advancement towards commercially viable drug product manufacturing, meeting FDA cGMP, is on target for later in 2026.

Negatives

• A portion of patients (6 cSCC and 1 metastatic melanoma) in the Phase 1b trial showed a pathologic non-response (<50% clearance).
• The toxicology study, a critical prerequisite for human pivotal trials, will not commence until Q1 2026, indicating a lead time before further human trials can begin.

Risks

• Actual results may differ materially from forward-looking statements due to inherent uncertainties, risks, and changes in circumstances.
• Risks include the outcomes from preclinical and clinical activities.
• The company's ability to execute on business strategies.
• The timing or likelihood of regulatory filings and approvals.
• The company's ability to manufacture and supply product candidates for clinical activities and for commercial use if approved.
• The scope of protection the company is able to establish and maintain for intellectual property rights covering its technology platform.
• The company's ability to obtain future financing.
• Market and other conditions.

Future Outlook

Phio Pharmaceuticals anticipates that its INTASYL siRNA gene silencing technology will enhance the body's immune cells to more effectively kill cancer cells. The company expects PH-762 to potentially offer a viable non-surgical alternative for skin cancer. Management is focused on advancing the clinical strategy, development plans, and timelines for PH-762, with a toxicology study commencing in Q1 2026 and commercially viable drug product delivery targeted for later in 2026.

Management Comments

• "The conduct of this nonclinical study is a very significant step in progressing the drug development pathway of PH-762 toward an NDA approval."
• "Phio's communication with FDA is essential in advancing our development strategy for PH-762."
• "In addition, the initiative to deliver commercially viable drug product from our US supplier is on target for later in 2026. This is another critical advancement in the drug development program of PH-762."

Industry Context

This announcement highlights the ongoing advancements in immuno-oncology and gene silencing technologies, particularly siRNA, for cancer treatment. The focus on non-surgical alternatives for skin cancers like cSCC, melanoma, and Merkel cell carcinoma aligns with a broader industry trend towards less invasive and more targeted therapies. Successful progression through FDA regulatory milestones, such as toxicology studies, is critical for all biopharmaceutical companies in bringing novel drugs to market, positioning Phio Pharmaceuticals within the competitive landscape of cancer drug development.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive drug development milestones and regulatory progress, but also continued investment in R&D.
• Patients: Potential for a new, non-surgical treatment option for various skin cancers, especially given the positive interim efficacy and safety data.
• Employees: Continued employment and focus on advancing the PH-762 program.
• Regulatory Authorities (FDA): Ongoing engagement and review of Phio's drug development process.

Next Steps

• Commencement of the toxicology study for PH-762 in the First Quarter 2026.
• Continued initiatives to advance the delivery of commercially viable drug product in 2026 that meets FDA's current Good Manufacturing Practices.
• Progression of PH-762 toward an NDA approval.

Key Dates

Recommendation

The FDA's acceptance of the nonclinical study design and the positive interim Phase 1b results for PH-762 are significant positive developments, indicating strong progress in the drug's development pathway. The safety profile appears favorable, and the observed complete responses are encouraging. However, the toxicology study is still in Q1 2026, and a human pivotal trial is further out, meaning commercialization is not imminent. While the news is positive, the company remains a clinical-stage biopharmaceutical firm with inherent risks associated with drug development, including future trial outcomes, regulatory approvals, and financing needs. The reference to a 'recent financing' suggests ongoing capital requirements. Given the positive but early-stage nature of the progress and the long road ahead to market, a 'hold' recommendation is appropriate for investors already in the stock, while new investors might wait for further de-risking milestones.

Keywords

Phio Pharmaceuticals, PHIO, PH-762, INTASYL, siRNA, Immuno-oncology, Cancer Treatment, Skin Cancer, Cutaneous Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, FDA, Toxicology Study, Clinical Trial, Phase 1b, Drug Development, Biopharmaceutical